What is known and objective: Pseudomonas aeruginosa is the leading cause of lung infection in patients with cystic fibrosis (CF) and is associated with significant morbidity and mortality. Antibiotics are regarded as the foundational pharmacological treatment for the suppressive management of chronic P. aeruginosa infections and to eradicate the first infection by P. aeruginosa. Inhalation remains a preferred route for drug administration, providing direct access to the site of infection while minimizing systemic side effects. Effective suppressive management of P. aeruginosa infections, however, requires an understanding of the location of the bacteria in the lungs and consideration of the factors that could limit access of the inhaled antibiotic to the infected area. This review provides a systematic assessment of the scientific literature to gain insight into the location of P. aeruginosa in the lungs of patients with CF and its clinical implications. The characteristics of antibiotic inhalation systems are also discussed in this context.
| WHAT IS KNOWN AND OBJECTIVE
can be resistant to antibiotic treatment. 2 Reduction in the levels of fluid in the lower lungs prevents clearance of mucus plugs and microorganisms from the airways. Chronic lung infection causes an influx of cellular infiltrates and inflammatory cells, such as polymorphonuclear leucocytes that stimulate pro-inflammatory cytokine release and chronic lung inflammation and can impair lung function. 3 As CF affects other organ systems, patients also experience intestinal malabsorption of fat, meconium ileus, impaired liver function and male infertility. 4 Cystic fibrosis is a progressive disease, where P. aeruginosa transitions from a non-mucoid strain that does not form biofilms and is located predominantly in the conducting airways, to a mucoid strain that forms biofilms and is present throughout the lungs. Chronic P. aeruginosa infection in the lower airways is known to correlate with declining lung function and worsening disease status, which accounts for disease-related morbidity and mortality in 60-80% of patients. 5, 6 Antibiotic inhalation remains a preferred route of administration for alleviating CF symptoms, enabling drug delivery directly to the desired site while minimizing systemic side effects. Early treatment with nebulized and dry powder inhaler (DPI) antibiotic formulations can be used in attempts to eradicate the first infection of P. aeruginosa.
However, with the progressive nature of CF and change in P. aeruginosa phenotype, the treatment strategy changes from one focused on eradication to one of chronic suppression. Accordingly, published guidelines recommend inhalation of antibiotics to allow effective control and suppression of chronic P. aeruginosa infection in lungs. 7 Patients need to self-administer their medication due to the chronic nature of CF, and the treatment outcome depends significantly on their inhalation technique and correct use of the device (eg inhaler or nebulizer). Additionally, clinical success of the treatment would depend on the location of P. aeruginosa in the lungs. The lung can broadly be divided into two zones, the smaller conductive zone that forms the passage for air to enter and exit the lungs, and the larger respiratory zone (in terms of surface area) where gaseous exchange takes place.
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Inhaled antibiotics (eg tobramycin, colistin) are generally deposited in higher concentrations in the conductive zone, with less deposition in the respiratory zone. 9 Conversely, systemic antibiotics (eg azithromycin, ciprofloxacin) generally deposit at very low concentrations in the conductive zone but at higher concentrations in the respiratory zone,
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depending on the physico-chemical properties of the active substance. Another important factor to consider is the subpopulations of microorganisms in the biofilm. During chronic infection, P. aeruginosa populations can adapt to the conditions in the microenvironments of biofilms and develop antibiotic resistance, leading to phenotypic diversity among transmissible bacterial strains. 10 As such, surviving bacterial strains that resist antibiotic treatment (persister cells) can repopulate the biofilms upon treatment alleviation.
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Pseudomonas aeruginosa is known to colonize and persist in many regions of both the conductive and respiratory zones of the lung, but a comprehensive review of where P. aeruginosa resides in the lungs does not currently exist. Here, we present a systematic narrative review of human and animal studies comprising data or discussion with respect to P. aeruginosa lung location. We also assess the clinical implications of the P. aeruginosa lung location data, and the relevance to current inhalation drug delivery systems.
| METHODS
We reviewed evidence-based literature from both human and animal studies in which P. aeruginosa lung location was reported. Keywords used in OVID database searches were "P. aeruginosa" or "pseudomonas," and "bronchi" or "lower respiratory tract" or "lumen" or "peripheral respiratory" or "upper respiratory tract" or "lung" or "pulmonary," and "cystic fibrosis" or "CF," and "colonies" or "colonization" or "colony". Publications were identified as relevant through a screening strategy (Figure 1 ), and these are summarized by reported P. aeruginosa location in Figure 2 . The findings from the search are presented as a narrative review.
| RESULTS AND DISCUSSION

| Location of P. aeruginosa in lung airways
The conductive zone consists of the extreme upper regions of the airways (nasopharynx, sinuses), the trachea, bronchi, terminal bronchioles, and contains cilia and submucosal glands that produce mucus/ sputum. In contrast, the respiratory zone, which has a much larger surface area and includes respiratory bronchioles, alveolar ducts and alveolar sacs, does not have cilia or mucus-secreting glands. Analysis of the scientific literature suggests that both of these zones can be infected with P. aeruginosa. CF infection involves multiple microorganisms that are known to be spatially heterogeneous, 12 meaning that both bacterial density and local disease progression can differ between the different lung lobes.
| Upper airways/conductive zone
General P. aeruginosa colonization in the conductive zone of the lungs, both in humans and rodent models, has been reported in multiple studies and covered by previous review articles. 4 Using lung blocks and post-mortem material from patients with CF, early studies reported P. aeruginosa colonization in multiple locations of the small airways from the small bronchi to the alveolar sacs. 51, 52 In one of these studies, the highest concentration of P. aeruginosa was found in the small bronchioles, which correlated with the area of most severe physiologic lung damage. 52 Subsequent studies have confirmed the presence of P. aeruginosa in multiple locations within the lower airways of patients with CF. 53, 54 A study assessing bacterial load by bronchoalveolar lavage (BAL) in paediatric patients with CF found that some patients had considerable differences in bacterial density (including P. aeruginosa) between the two sampling sites-the right middle lobe and the lingular bronchus-suggesting that multiple lung sites should be sampled when performing BAL in infants. 55 Rodent models of CF and/or P. aeruginosa colonization are commonly used to discriminate between specific lower lung regions in more detail than would be feasible with human patients with CF, and these studies have reported P. aeruginosa infection in discrete lower airway locations, including the respiratory bronchioles, parenchyma and alveoli.
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| Clinical implications of P. aeruginosa lung location in CF
When the literature is considered as a whole, it is clear that most areas of the conductive and respiratory zones are susceptible to P. aeruginosa colonization. Nevertheless, for an individual patient with CF, heterogeneity can often exist in both P. aeruginosa colonization and disease location, and so ideally, clinicians would be able to individualize treatments for each patient to target the drug to regions infected with P. aeruginosa.
| Identifying location of P. aeruginosa infection
In clinical terms, specific areas of the lung colonized by P. aeruginosa firstly need to be identified, if possible, and secondly need to be treated using a single therapy, or a combination of therapies that will deposit the drug effectively-achieving eradication, greater bacterial killing or other outcome measures, such as improved lung function, reduced exacerbations, reduced hospitalizations and improved quality of life (QoL). P. aeruginosa colonization in patients with CF is routinely identified by sputum cultures, which are useful to confirm infection but are unable to offer much information on which specific respiratory zone regions are affected. Another confirmatory method for the detection of P. aeruginosa involves the chemical analyses of volatile organic compounds in exhaled breath samples. 61 More precise localization of P. aeruginosa infection is possible in the oropharynx, nasal passage and sinuses using routine swabbing techniques, due to the relative ease of access. To reveal specific locations of infection in the respiratory zone, invasive techniques, such as bronchoscopy with protected specimen brush and/or BAL, are needed. Although these techniques were reported to be less reliable than sputum collection for sampling airway flora in adult patients with CF, 62 they are potentially useful in paediatric patients with CF who cannot produce sputum. 63 Alternatively, non-invasive imaging methods, such as chest radiography or computed tomography (CT) scan, can be employed to detect localized areas of infection and associated inflammation in the lower airways. The advantages and disadvantages of established and emerging imaging techniques have been reviewed previously. 
| Drug concentration
Pharmacodynamic parameters are typically used to quantify antimicrobial activity, such as the minimum inhibitory concentration (MIC), which is the lowest concentration of antimicrobial required to inhibit visible growth of a microorganism following overnight incubation in vitro. 65 Due to the likelihood of microbial and disease heterogeneity in patients with CF, an effective delivery system that can target P. aeruginosa in both the respiratory and conductive zones, or even in a specific lobe, is required. The latter is important because certain parts of the lungs may not be well preserved due to structural changes caused by the disease. This situation may potentially lead to ineffective treatment of the diseased lung regions, particularly if the antibiotic delivered to the obstructed areas is below the minimum inhibitory concentration (MIC), and instead preferentially deposited in the ventilated areas of the lungs. 66 Additionally, a single species of the infective microorganism may exhibit a wide MIC range, 67,68 which reiterates the importance of achieving effective deposition of the antibiotic throughout the bronchial tree and at levels above the MIC. While it is possible, in principle, to deliver the majority of the lung dose to the respiratory zone, the resulting concentrations of drug in the lung periphery may still be below the MIC due to the large surface area of the respiratory zone relative to the conducting zone (Figure 3 ), a situation that can also lead to increased bacterial mutagenesis and antibiotic resistance. 69 While achieving high concentrations in the lung periphery may seem like a reasonable goal, there are both practical and structural limitations which may render this difficult to achieve.
The formation of biofilms causes the infected sites to become less accessible to antibiotics, and hence, increased concentrations of drug F I G U R E 3 Hypothetical drug deposition pattern in the lungs and correlation with airway surface area. *Dependent on drug delivery system are required to achieve the MIC. Another parameter that can be used to quantify antimicrobial activity is the minimal biofilm-eradication concentration (MBEC), which is the lowest concentration of the antibiotic required to eradicate the biofilm. 70 It is important, therefore, to consider both the MIC and MBEC when quantifying antimicrobial activity and determining drug delivery.
The gold-standard drug for killing P. aeruginosa in patients with CF is tobramycin, which acts in a concentration-dependent manner (as do the aminoglycosides and fluoroquinolones); that is, the rate and extent of killing increase proportionally with the peak drug concentration. This property of tobramycin is in contrast to the time-dependent manner in which the beta-lactams and vancomycin act, whereby bactericidal activity continues as long as the drug concentration is above the MIC. 
| Drug combinations
Depending on the delivery device and formulation used, combining inhaled and systemic antibiotics would enable targeting the whole lung from the outset. Treatment with inhaled colistin and oral ciprofloxacin has been shown to offer protection from the development of chronic P. aeruginosa infection in patients with CF. 72 This approach leads to minimal development of antibiotic resistance in P. aeruginosa.
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Combining different antibiotics can also enable the targeting of different subpopulations of microorganisms in the biofilm. 
| Delivery method
The concentration of the inhaled antibiotic delivered to various regions in the lungs is dependent on a number of factors, such as delivery method, flow rate, lung function (ie inspiratory effort), particle size, patient anatomy, disease state and mucous plugging. The delivery method, in particular, can largely influence the achievable amount of antibiotic deposition in the lungs. [74] [75] [76] It will be interesting in future studies to perform comparisons of different delivery methods in patients with CF, in whom the efficacy of the treatment and QoL can be ascertained and correlated with lung deposition data.
| Non-mucoid to mucoid transition
The respiratory zone of the lungs, in particular, can become colonized by mucoid alginate-overproducing P. aeruginosa microcolonies, which become surrounded by areas of polymorphonuclear leucocyte (PMN)-induced inflammation leading to lung damage. 49 An intriguing question is whether the transition of P. aeruginosa from a non-mucoid to mucoid phenotype, caused by mutations in the algU, mucA and mucB genes 77, 78 and subsequent selection, can directly cause bacterial redistribution to the lower airways and thereby contribute to the difficulty in the eradication of mucoid P. aeruginosa? To our knowledge, this specific question and the clinical implications are yet to be addressed in the literature. Following the transition from non-mucoid to mucoid, and the chronic colonization of the lower lungs, the ability to eradicate P. aeruginosa becomes much more challenging and so the treatment strategy typically becomes focused on suppression.
| Lung health
While it is vital to gain insight into drug deposition in the lower airways, it is our view that treatment strategies for chronic P. aeruginosa infection should change from achieving improvements in lung function to maintaining lung health. Functional respiratory imaging is a novel approach that combines CT and computational fluid dynamics (CFD) to present a three-dimensional view of the airways, their geometry, regional airway resistance and drug deposition patterns. 66, 79 This approach may provide the key to personalized delivery, as it could allow detection of changes in lung health before they become apparent using lung function measurements, while also accelerating the identification of promising treatments and effective delivery systems.
The extensive amount of clinically relevant information that this imag-
ing technique provides could not only be used to assess desired drug deposition pattern in the lungs, but also to provide insight into how various factors (patient-and formulation-related) influence deposition of the antibiotic. This approach could also potentially complement pharmacokinetic and scintigraphic approaches that do not accurately estimate the regional deposition of antibiotics. The important implication of this technique is that it provides data related to local deposition of the drug in specific sites of the lower airways and can identify regions in the lungs that are not being treated effectively. 
| Mucus plugs
The combination of CF-related reduction in water efflux and a buildup of mucoid P. aeruginosa microcolonies results in so-called hypoxic mucus plugs that can block access to the lower airways. 20 Airway clearance, including removal of mucus plugs, by methods such as direct hydration, physiotherapy or CFTR modulation is, therefore, often a necessary first step prior to delivery of antibiotic to the site of infection. 80 Cough has also received attention as a means of facilitating removal of secretions from the airways so that it can be easily expectorated, especially in patients with impaired mucociliary clearance.
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The air flow produced during a forceful cough may generate shear forces to loosen up the mucus plugs before they can be discharged from the airways. Incorporation of cough sessions into the treatment regimen has been shown to be as effective as therapist-administered physiotherapy in removing airway secretions. 82 However, a study in patients with stable chronic obstructive lung disease revealed that although cough was effective in enhancing clearance from the central airways, it offered limited clearance of the peripheral regions. 83 The impact of the above-mentioned approaches in aiding expectoration of sputum can be assessed by way of auscultation, spirometry, pulse oximetry, health-related QoL, breathlessness, and estimation of sputum weight or volume. 84 A delivery system that could remove mucus plugs, possibly by rapid oscillation or altering pressure, while subsequently delivering antibiotic would be beneficial.
| Nasal areas
Regarding the sinuses and nasal areas, it would be interesting to look at the phenotype of P. aeruginosa in the nose. As the nasal areas are not usually targeted by inhaled or i.v. antibiotics, oxidative stress in the milieu of the nose may be very different than that in the lungs, as there may be little driving force for P. aeruginosa to form mucoid strains. This situation could be important if mucoid P. aeruginosa was eradicated from the lungs, because under such a scenario, the question arises as to whether the lungs would then subsequently colonize with wild-type or non-mucoid P. aeruginosa from the nasal areas, which could then be eradicated for some period of time. Methods to deliver drug to the nose in order to eradicate nasal P. aeruginosa should be explored.
| Inhalation drug delivery systems
A variety of inhalation drug delivery systems are used by patients with CF, with the two most common device types being nebulizers and DPIs, the latter of which is favoured by the majority of new product launches for general respiratory drug delivery. 85 It has been suggested that an ideal inhalation device would have the following attributes:
effectiveness (ie ability to deliver drug into both zones effectively), reproducibility, precision, stability, comfort (ie ease of use), versatility, environmental compatibility and affordability. 86 When considering P. aeruginosa lung location, as discussed above, the question arises as to what specific characteristics of an ideal device are most important for treating P. aeruginosa in patients with CF?
First and foremost, the combination of device and inhaled drug should be capable of targeting sites of P. aeruginosa infection in both lung zones, in order to provide sufficient localized antibiotic concentration to ensure efficient killing of bacteria, including dormant/ resistant cells that can seed subsequent regrowth. Progression of CF disease (eg bronchiectasis, mucus plugs) impacts the ability to deliver aerosols into the lung periphery, just as the infection progresses into the deeper lung with greater destructive capability.
Ease of device usability is of vital importance for the patient, as a device and treatment schedule that has minimal impact on their dayto-day activities will promote adherence and improve outcomes. 87 An ideal device should, therefore, come with clear instructional steps to prevent device errors, that is adherence, preparation and/or inhalation errors. 88 An added benefit of an ideal device would be the ability to co-administer drugs to assist in bronchodilation and unblocking mucus plugs, thus allowing for more effective delivery of the antibiotic to the relevant lung locations. Indeed, a single therapy involving airway clearance followed by antibiotic delivery would be welcomed by the CF community (ie airway clearance, bronchodilation, mucolytic treatment, then finally antibiotic delivery), although making such fixeddose combinations with antibiotics would be challenging due to the high-dose requirements.
A recent review of inhaled antibiotic therapy, and the common devices used in CF, concluded that to maximize the utility of aerosolized antibiotics, we must first gain a better understanding of the factors contributing to antibiotic resistance and also develop treatment regimens that are unconducive to resistance and effective in eradicating bacteria. 88 One factor known to contribute to resistance is the delivery of antibiotics to the site of infection in concentrations below the threshold required to effectively kill both susceptible and resistant bacteria. 89 To prevent this situation in the treatment of patients with CF, the physician needs to be confident that the chosen antibiotic delivery device is capable of consistently targeting the drug to these regions in sufficient concentrations to effectively kill all bacteria. In this respect, factors such as drug formulation, air flow velocity and restrictions due to device resistance and reduced lung function must all be considered when choosing an appropriate drug and device.
With respect to burden of treatment, DPIs give time back to patients when compared to nebulizers, through more rapid administration and delivery, but also additional maintenance time is saved as DPIs do not require as much cleaning as nebulizers. 90 These time-saving aspects of DPIs are thought to contribute to improved adherence and QoL in patients using these devices. 91 DPIs also prevent loss of the loaded drug upon administration, as compared to most nebulizers.
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Furthermore, there is a limit to the number of capsules constituting a dose and the length of time required for a treatment. For aerosols, this limits the total lung dose to something on the order of 100 mg or less based on products on the market. Based on this limit, along with factors such as surface area, epithelial lining fluid thickness and estimates of drug biodistribution, it may be unfeasible to achieve effective drug concentrations in the lung periphery using currently available aerosols.
A limitation of some DPIs is that they are breath-actuated and drug deposition, due to formulation characteristics, is dependent on the inhalation profile generated by the patient. Adult patients with CF with significant declines in lung function can still generate significant flow rates, and so this limitation is mainly a concern for paediatric patients with CF <6 years of age who have yet to develop sufficient muscle strength, or who are cognitively unable to use a DPI effectively. This necessitates that the DPI should offer minimum resistance to airflow so that it can be used by young children. In spite of this limitation, DPIs are relatively convenient to use, and features such as portability, quick administration time and less time required for cleaning 88 have purportedly led to their increased acceptance.
| WHAT IS NEW AND CONCLUSION
It is clear that P. aeruginosa is present ubiquitously throughout the bronchial tree of patients with CF and the structural damage to the lung tissue results in blockage of airway passages. Deposition of an inhaled antibiotic depends on device and formulation characteristics (dependent on device airflow resistance, particles size, deagglomeration, etc.) and the ability of the patient to generate sufficient inhaled volume (disease status, dependent on lung capacity, extent of airflow limitation due to structural changes, etc.). As patients with CF often experience a decline in lung function, this can prevent them from generating sufficient inspiratory effort required to inhale the antibiotic via the chosen delivery system. The challenge is to overcome these limitations so that the inhaled antibiotic can be delivered above its MIC throughout the bronchial tree to enhance the killing of bacteria in the relevant lung locations.
Considering that patients with CF typically take numerous medications in addition to antibiotics, the time spent on self-administration may add to the treatment burden. Nebulizers have been regarded as inconvenient to use, 75 which can lead to poor compliance and increased risk of hospitalization, 92 and are known to be less efficient in delivering drug into the lower parts of the lung where P. aeruginosa is located. 4 Despite the evident gap between treatment and compliance, the importance of an ideal inhaler is not adequately addressed by the current guidelines. Effective disease control and treatment require selection of an appropriate pharmacological agent along with consideration of an appropriate device for delivery of the medication. The chosen inhalation device should offer a drug formulation that can be quickly and conveniently delivered at high concentrations to the airways of the lungs with minimum inspiratory effort from the patients, so that it can be used even by paediatric patients and those with severely impaired lung function. This approach would improve compliance to the prescribed treatment regimen and lead to better treatment outcomes. 87 The fact that the use of conventional nebulizers is familiar to many patients with CF, and that they are amenable to the use of waterbased antibiotics, means that nebulization as a delivery method is still of value, perhaps particularly for passive administration in paediatric patients and for medically compromised patients with acute exacerbations who are unable to actively use alternative devices.
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Furthermore, it seems clear that delivery of antibiotics to the nasal areas and sinuses, a region known to act as a reservoir for microorganisms, would be most effectively achieved through nebulization with use of a facemask.
Recent developments in DPI technology and particle engineering have enabled improved drug deposition, with comparable safety and convenient administration compared to nebulizers. 88, 94, 95 The future of pulmonary drug delivery might eventually be personalized to each patient to ensure controlled and targeted delivery to the lungs, 94 thereby giving physicians the ability to target specific lung locations colonized with P. aeruginosa in patients with CF. Perhaps this may need a better understanding of not only the structural changes in the lung airways but also an insight into the biochemical changes in the diseased area of the lungs compared to healthier regions. Functional respiratory imaging is a step forward in this direction to assess structural changes and drug deposition patterns. 66, 79 This imaging approach, or similar technologies, used together with inhalation devices capable of delivering antibiotics to all areas of the bronchial tree, would provide patients with CF with personalized treatment options involving controlled and targeted delivery of antibiotics and aid in the ultimate goal of achieving eradication of P. aeruginosa, improving lung health and restoring lung function.
